A judicial officer has determined NephroSant Inc.'s former CEO should lose a bid to keep certain information confidential in Delaware Chancery Court litigation she filed seeking to have the kidney disease treatment startup cover the legal costs of defending herself from allegations over the company's novel urine tests.